Rethinking Early‑Phase Oversight
Early-phase oversight fails when data is fragmented, and true clinical confidence only comes from seeing signals in full context.
Early-phase oversight fails when data is fragmented, and true clinical confidence only comes from seeing signals in full context.
Excel may feel familiar, but its hidden gaps undermine subject review and create risk long before teams can see it.
Oncology R&D is evolving through precision, disciplined portfolios and pragmatic AI integration.
A deeper look at the recurring FDA warning letter findings that reveal whether your computer system validation is truly under control.
Clinical trials may look stable on paper but rising rare disease, CNS and cardiovascular complexity is exposing old operating models.
Speech data is emerging as a new way to track behavioural changes in clinical trials.
The UK’s clinical trials sector is gaining real momentum giving sponsors new confidence to bring studies back.
2026 marks a turning point for Risk-Based Quality Management as ICH E6(R3) moves from theory to practice.
In 2026, compliance will hinge on RBQM integration, a governance loop that links risk with audit-ready evidence.